What's the point of developing new drugs?

This question is not rhetorical. A new treatment to lower harm from a minor respiratory virus in infants instead is associated with MORE baby deaths, clinical trials show. Yet no one seems to care.

Two years after Covid jabs turned into the world’s best-selling pharmaceutical product, Big Pharma is chasing billions from new products for another airborne illness: respiratory syncytial virus, or RSV.

Two European drug companies, AstraZeneca and Sanofi, want the Food and Drug Administration to approve a costly new treatment called nirsevimab for RSV f…